Zydus Lifesciences' ZyVac TCV Typhoid Vaccine Gets WHO Approval

Oct 23, 2024, 05:24 AM

Zydus Lifesciences Ltd announced on Wednesday that its Typhoid Vi conjugate vaccine, ZyVac TCV, has received in-principle approval from the World Health Organization (WHO). This prequalification marks a significant step for the company in addressing typhoid, a serious infectious disease. The WHO prequalification is essential for global health initiatives as it ensures the vaccine meets international standards for quality, safety, and efficacy. This approval will potentially enhance Zydus Lifesciences' market reach and contribute to global efforts in combating typhoid.